AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00262938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
Study NCT00262938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preventative dietary intervention
Description: Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
Study NCT00262938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
Study NCT01540955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Cognition with group intervention
Description: Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
Study NCT03000439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In open-label phase: treatment with tofacitinib
Description: Treatment with investigational drug
Study NCT03000439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Description: Treatment with investigational drug or placebo
Study NCT03000439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Description: Treatment with investigational drug or placebo
Study NCT03213171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reception staff providing handout.
Description: Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation
Study NCT03213171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Tablet (e.g. iPad)
Description: Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
Study NCT01421472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
Study NCT01421472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
Study NCT01421472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
Study NCT02491294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family
Description: students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
Study NCT02491294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: About Eating
Description: parents who completed the parent survey are invited to access the 6 lesson online About Eating program
Study NCT01914562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 10 mg
Description: OCA 10 mg tablet oral
Study NCT01914562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 25 mg
Description: OCA 25 mg tablet oral
Study NCT03516344 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver pumping and Spinal manipulation
Description: Interventions are described in group descriptions
Study NCT00049088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00049088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00049088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00049088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01517477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of One iStent through a small temporal clear corneal incision.
Study NCT01517477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of Two iStents through a small temporal clear corneal incision
Study NCT01517477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of Three iStents through a small temporal clear corneal incision
Study NCT02467530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGE
Study NCT01785212 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stapler
Description: stapler hepatectomy
Study NCT01785212 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)
Description: CUSA is a well established device used for hepatic resection using ultrasound
Study NCT00929071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolence
Description: Injectable collagen
Study NCT00929071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: admix anesthetic
Study NCT00929071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical anesthetic
Study NCT01848535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: GOS addition
Description: GOS (2.5g 3x per day) supplemented during 12 days
Study NCT01848535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrine(2.5g 3x per day) supplemented during 12 days
Study NCT04668352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactolisib
Description: TORC1 inhibitor
Study NCT04668352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01976559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanic Membrane Displacement (TMD)
Description: The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.
Study NCT01976559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DPOAE
Description: DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
Study NCT03008395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMMA
Description: Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
Study NCT03008395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
Study NCT02679469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene hydrochloride 10 mg
Study NCT03739073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OCTA (angiography by tomography in optical coherence)
Description: The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.
Study NCT02809287 — intervention group
Intervention type: PROCEDURE
Intervention: Jackknife posture
Description: patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
Study NCT01079481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxol plus everolimus
Description: taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
Study NCT00300638 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
Study NCT00300638 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews, cognitive tests, and emotional measurements
Description: We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
Study NCT02935400 — intervention group
Intervention type: DRUG
Intervention: Hemin
Description: Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.
Study NCT03473561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril plus ORS
Description: 1.5 mg/kg of Racecadotril will be administered, 3 times daily, via the oral route (in addition to standard treatment i.e. oral rehydration solution).~In infants less than 9 kg: one 10 mg sachet 3 times daily. In infants from 9 kg to \< 13 kg: two 10 mg sachets 3 times daily. In children from 13 kg to 27 kg: one 30 mg sachet 3 times daily. In children of more than 27 kg: two 30 mg sachets 3 times daily.
Study NCT03376672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: All patients will have similar induction and consolidation treatment with the same regimen.
Study NCT03376672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All patients will have similar induction and consolidation treatment with the same regimen.
Study NCT03376672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All patients will have similar induction and consolidation treatment with the same regimen.
Study NCT01175044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Betadine Lavage
Description: Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
Study NCT01175044 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline Lavage
Description: Following revision knee surgery, 2000ml sterile saline lavage prior to closure
Study NCT01266486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Extended release Metformin 1500mg once daily for 14-21 days
Study NCT02294513 — intervention group
Intervention type: DEVICE
Intervention: Standard audiologic rehabilitation (incl. HI)
Description: The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
Study NCT01553838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided prostate biopsy and TRUS guided biopsy
Description: MRI guided prostate biopsy
Study NCT00565448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study NCT00565448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study NCT00565448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study NCT00272987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: (GW572016) 1000 mg QD
Study NCT01175083 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (Synflorix)
Description: 2, 3 or 4 intramuscular injection
Study NCT01175083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (Synflorix)
Description: 2, 3 or 4 intramuscular injection
Study NCT01175083 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib
Description: Intramuscular injection, 4 doses
Study NCT01175083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib
Description: Intramuscular injection, 4 doses
Study NCT01175083 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin
Description: 4 oral doses
Study NCT01175083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin
Description: 4 oral doses
Study NCT02302612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CREATE Wellness
Description: Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program
Study NCT02302612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
Study NCT00753246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: monoclonal antibody
Study NCT00753246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nimotuzumab
Description: monoclonal antibody
Study NCT04303676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Practice Facilitation with e-Learning
Description: Virtual practice facilitation intervention using e-learning modules to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (combination of virtual academic detailing plus online training resource) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist.~c. Resources largely included as part of the e-learning module, but supplemented by online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ.
Study NCT04303676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Practice Facilitation without e-Learning
Description: Virtual practice facilitation intervention without e-learning to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (virtual academic detailing) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist c. Online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ.
Study NCT03176537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Androgel (50mg testosterone), gel, daily
Study NCT03176537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo, gel, daily
Study NCT01335737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 12 weeks of aerobic training, 4 times/week
Study NCT01335737 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list
Description: wait list control condition
Study NCT04342507 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conservative treatment
Description: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.
Study NCT04342507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.
Study NCT04342507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of adults chalazia by re-establishing intestinal and immune homeostasis
Study NCT03241030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: Will receive 20mg/kg/dose up to 1 gram.
Study NCT03241030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
Study NCT00565448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study NCT00565448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study NCT03241030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Study NCT03241030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Study NCT03241030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Study NCT03241030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Study NCT04313413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga sessions includes sukshma vyayama (strengthening yoga expertise), stretching and relaxing postures (asana) on chair or standing, breathing and meditation practices.
Study NCT01068964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution
Description: One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
Study NCT01068964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution
Description: One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
Study NCT02091557 — intervention group
Intervention type: DRUG
Intervention: GnRH-analogue
Study NCT04215302 — intervention group
Intervention type: DEVICE
Intervention: laryngeal mask
Description: the size of laryngeal mask given to the patient was based on patient's weight measurement
Study NCT00615901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
Description: C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
Study NCT02902341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Therapy
Description: Nutrition based on measured caloric needs.
Study NCT02902341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard protocol nutrition based on calculated caloric needs.